Member Info for iaintgotaclu

Whats going on here then guys

BBOOOOM todays bagger then

#TILS $TLSA - From 3M 30 secs onwards - direct head to head against Oncotype - which showed a SUBSTANTIAL SUPERIORITY! There are going to be some unhappy folks at Exact Sciences 6 mins 12secs- talk about $2.8bn down the drain. https://twitter.com/andrewscotttv/status/1260821159156817920

creating an entirely new business line beyond our current patented technology

if you had paid 2.8 billion to have Oncotype as the market leader and then the same company come out with StemprintER which is SUPERIOR to it what you be thinking ??? take them out for 2 Billion or 3 Billion as they now have the best product 2 add 2 =9

When you consider Oncotype owner Genomics was taken over by Exact Science only last November for $2.8bn and now you know $TLSA #TILS have a better product at $140m mcap you dont need to say much else!

Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences. "This product also represents an important addition to our existing therapeutic pipeline as it opens Tiziana into the area of precision medicine, creating an entirely new business line beyond our current patented technology in offering new delivery mechanisms for monoclonal antibodies."

Here you go its live but you will need to refresh

https://stocktwits.com/symbol/TLSA

10pm our time UK

there is an announcement coming tonight mate a big announcement

this isn't the embargoed http://ASCO.org info, it's from an earlier report written by the same author ... gives us the flavour of what is coming tomorrow.

https://t.co/kVfON0yl54?amp=1 here is the link

here is the juicy part..

"to outperform first generation BC prognostic tests - e.g., Oncotype DX [47] and Mammaprint [48] "

"We therefore submit that, by its unique ability to interrogate the “stemness” of individual BCs, StemPrintER might prove clinically valuable, either as a standalone test or in combination with other genomic predictors or clinicopathological parameters, to guide individualized clinical decision-making in Luminal BC patients."

StemPrintER is better than Oncotype and that sold for $2.8bn

asher with news expected tonight this goes a lot higher than a £

"This places StemPrintER among the more recently developed second generation multi-gene assays....which have been shown to outperform first generation BC prognostic tests - e.g., Oncotype DX and Mammaprint"

https://thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30114-8/fulltext

https://t.co/kVfON0yl54?amp=1

Anyone seen this just been posted on twitter

https://twitter.com/smacker_aim/status/1260554356191047681?s=20

TILS Oh my days. Just found that the expert doing the ASCO report on StemPrintER has already produced a report in March on a medical website.

"clinically valuable" Looks like it's going to be positive!!

https://sperotherapeutics.com/

CW’s LinkedIn suggests that they’ve recently completed some form of study...could it be relevant?

SPER therapeutics